Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors

Immunotherapy, as the fourth major cancer treatment method, has made breakthrough progress in the field of cancer therapy. Immune checkpoint inhibitors (ICIs) have been extensively utilized in the management of diverse malignant neoplasms, with a substantial corpus of clinical evidence and experience accumulating in the field of gynecological oncology. This article reviews the clinical application strategies of ICIs, either alone or in combination with radiotherapy and chemotherapy, targeted therapy, etc., for gynecological malignant tumors such as cervical cancer, endometrial cancer, ovarian cancer, and other malignancies. We summarized relevant progress from clinical trials with the aim of providing more effective precision immunotherapy strategies for patients with gynecological malignant tumors.